Each year, roughly 100,000 babies worldwide are diagnosed with a life-threatening condition called persistent pulmonary hypertension of the newborn (PPHN). In infants with PPHN, blood does not circulate properly through the lungs, and sufficient oxygen does not reach the heart, brain and other major organs. Yet, despite the proven effectiveness of inhaled nitric oxide (iNO) as a life-saving treatment for PPHN, access to it by patients has been severely limited—in part because of its expensive, unwieldy system of delivery…
